Eris human insulin
Insulin human biosimilar developed by Eris Lifesciences. Reference product Humulin (Lilly); Actrapid, Insulatard and Mixtard (Novo Nordisk); Insuman (Sanofi).
About Eris human insulin
Eris Lifesciences and its subsidiary Eris Bionxt received fourteen Indian permissions for human insulin between December 2025 and April 2026, covering the fast, intermediate and premixed forms in vials and cartridges, the broadest recent entry into Indian insulin manufacture.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Eris human insulin holds an approval, these are the other insulin human biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| CDSCO | 8 | Biocon Biologics (Biocon human insulin), Cadila Pharmaceuticals (Cadila Pharmaceuticals human insulin), Epygen Biotech (Epygen human insulin), Gland Pharma (Gland Pharma human insulin), M.J. Biopharm (M.J. Biopharm human insulin), Not stated in the CDSCO list (Lupin human insulin), Regenix (Regenix human insulin), Sanofi (Shantha human insulin) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Eris Lifesciences: Eris insulin glargine.
Chronology
- CDSCODec 2025CDSCO permission granted
Sources
Planning insulin human biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant